There is literature indicating that DE is an isolated anomaly. During the bell stage of tooth formation, DE may occur as a result of an unusual growth and folding of the inner enamel epithelium and ectomesenchymal cells of dental papilla into the stellate reticulum of the enamel organ. Diagnosis
Diagnosis of DE can be difficult when there is no signs and symptoms of necrotic or infected pulp. It is a challenging task to differentiate between a true periapical lesion and a normal periapical radiolucency of a dental follicle of an immature apex. Pulp tests (test results of immature teeth can be misleading, as they are known to give unreliable results)
Check and see if there is an elevated, flat wear facet on the occlusal surface of the tooth
Test cavity which has an absence of pain sensation and has an empty pulp chamber/ canal. Radiographs (usually periapical) - a V-shaped radiopaque structure could be seen superimposing on top of the affected crown. It could detect DE before tooth eruption. However, DE presentation on the radiograph can be quite similar to a mesiodens or a compound odontoma. Classification
The anterior DE tubercles have an average width of 3.5mm and length of 6.0mm, while posterior tubercles have an average 2.0mm in width and length of up to 3.5mm. If the cusp of Carabelli is present, the tooth associated are often larger mesiodistally and it is not uncommon that a DE involved tooth has an abnormal root pattern.There are 4 different ways to classify/ categorize DE involved teeth.
In another study that used an unspecified dosage of intramuscular OHPC, testosterone secretion was assessed in a single man and was found to decrease from 4.2 mg/day to 2.0 mg/day (or by approximately 52%) by 6 weeks of treatment, whereas secretion of luteinizing hormone remained unchanged in the man. Yet another study found that 3,000 mg/week OHPC by intramuscular injection suppressed testosterone levels from 640 ng/dL to 320–370 ng/dL (by 42–50%) in a single man with prostate cancer, which was similar to the testosterone suppression with cyproterone acetate or chlormadinone acetate. Gestonorone caproate, a closely related progestin to OHPC with about 5- to 10-fold greater potency in humans, was found to suppress testosterone levels by 75% at a dosage of 400 mg/week in men with prostate cancer. For comparison, orchiectomy decreased testosterone levels by 91%. In general, progestins are able to maximally suppress testosterone levels by about 70 to 80%. The antigonadotropic effects of OHPC and hence its testosterone suppression are the basis of the use of OHPC in the treatment of benign prostatic hyperplasia and prostate cancer in men. Suppression of luteinizing hormone levels by OHPC has also been observed in women. Glucocorticoid activity
OHPC is said not to have any glucocorticoid activity. In accordance, OHPC has been found not to alter cortisol levels in humans even with very high doses by intramuscular injection. This is of relevance because medications with significant glucocorticoid activity suppress cortisol levels due to increased negative feedback on the hypothalamic–pituitary–adrenal axis.